210 related articles for article (PubMed ID: 22309831)
1. Delayed caffeine treatment prevents nigral dopamine neuron loss in a progressive rat model of Parkinson's disease.
Sonsalla PK; Wong LY; Harris SL; Richardson JR; Khobahy I; Li W; Gadad BS; German DC
Exp Neurol; 2012 Apr; 234(2):482-7. PubMed ID: 22309831
[TBL] [Abstract][Full Text] [Related]
2. Adenosine A
Nunes ACL; Carmo M; Behrenswerth A; Canas PM; Agostinho P; Cunha RA
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732120
[TBL] [Abstract][Full Text] [Related]
3. Alteration in the progression of dopamine neuron degeneration: may caffeine offer new perspective?
Morelli M; Frau L; Simola N
Exp Neurol; 2012 Sep; 237(1):218-22. PubMed ID: 22705384
[No Abstract] [Full Text] [Related]
4. Pioglitazone Attenuates Neuroinflammation and Promotes Dopaminergic Neuronal Survival in the Nigrostriatal System of Rats after Diffuse Brain Injury.
Liu M; Bachstetter AD; Cass WA; Lifshitz J; Bing G
J Neurotrauma; 2017 Jan; 34(2):414-422. PubMed ID: 27142118
[TBL] [Abstract][Full Text] [Related]
5. Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degeneration.
Kachroo A; Irizarry MC; Schwarzschild MA
Exp Neurol; 2010 Jun; 223(2):657-61. PubMed ID: 20188092
[TBL] [Abstract][Full Text] [Related]
6. The angiotensin converting enzyme inhibitor captopril protects nigrostriatal dopamine neurons in animal models of parkinsonism.
Sonsalla PK; Coleman C; Wong LY; Harris SL; Richardson JR; Gadad BS; Li W; German DC
Exp Neurol; 2013 Dec; 250():376-83. PubMed ID: 24184050
[TBL] [Abstract][Full Text] [Related]
7. Blockade of Rapid Influx of Extracellular Zn
Tamano H; Morioka H; Nishio R; Takeuchi A; Takeda A
Mol Neurobiol; 2019 Jun; 56(6):4539-4548. PubMed ID: 30341553
[TBL] [Abstract][Full Text] [Related]
8. Peripheral administration of the selective inhibitor of soluble tumor necrosis factor (TNF) XPro®1595 attenuates nigral cell loss and glial activation in 6-OHDA hemiparkinsonian rats.
Barnum CJ; Chen X; Chung J; Chang J; Williams M; Grigoryan N; Tesi RJ; Tansey MG
J Parkinsons Dis; 2014; 4(3):349-60. PubMed ID: 25061061
[TBL] [Abstract][Full Text] [Related]
9. Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease.
McCoy MK; Martinez TN; Ruhn KA; Szymkowski DE; Smith CG; Botterman BR; Tansey KE; Tansey MG
J Neurosci; 2006 Sep; 26(37):9365-75. PubMed ID: 16971520
[TBL] [Abstract][Full Text] [Related]
10. Myricitrin Ameliorates 6-Hydroxydopamine-Induced Dopaminergic Neuronal Loss in the Substantia Nigra of Mouse Brain.
Kim HD; Jeong KH; Jung UJ; Kim SR
J Med Food; 2016 Apr; 19(4):374-82. PubMed ID: 26991235
[TBL] [Abstract][Full Text] [Related]
11. Anti-oxidant polydatin (piceid) protects against substantia nigral motor degeneration in multiple rodent models of Parkinson's disease.
Chen Y; Zhang DQ; Liao Z; Wang B; Gong S; Wang C; Zhang MZ; Wang GH; Cai H; Liao FF; Xu JP
Mol Neurodegener; 2015 Mar; 10():4. PubMed ID: 26013581
[TBL] [Abstract][Full Text] [Related]
12. IL-17A exacerbates neuroinflammation and neurodegeneration by activating microglia in rodent models of Parkinson's disease.
Liu Z; Qiu AW; Huang Y; Yang Y; Chen JN; Gu TT; Cao BB; Qiu YH; Peng YP
Brain Behav Immun; 2019 Oct; 81():630-645. PubMed ID: 31351185
[TBL] [Abstract][Full Text] [Related]
13. Post-treatment with an ultra-low dose of NADPH oxidase inhibitor diphenyleneiodonium attenuates disease progression in multiple Parkinson's disease models.
Wang Q; Qian L; Chen SH; Chu CH; Wilson B; Oyarzabal E; Ali S; Robinson B; Rao D; Hong JS
Brain; 2015 May; 138(Pt 5):1247-62. PubMed ID: 25716193
[TBL] [Abstract][Full Text] [Related]
14. The Kv7/KCNQ channel blocker XE991 protects nigral dopaminergic neurons in the 6-hydroxydopamine rat model of Parkinson's disease.
Liu H; Jia L; Chen X; Shi L; Xie J
Brain Res Bull; 2018 Mar; 137():132-139. PubMed ID: 29174294
[TBL] [Abstract][Full Text] [Related]
15. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
16. Inflammatory process in Parkinson disease: neuroprotection by neuropeptide Y.
Pain S; Vergote J; Gulhan Z; Bodard S; Chalon S; Gaillard A
Fundam Clin Pharmacol; 2019 Oct; 33(5):544-548. PubMed ID: 30866091
[TBL] [Abstract][Full Text] [Related]
17. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
[TBL] [Abstract][Full Text] [Related]
18. Caffeine: An Overview of Its Beneficial Effects in Experimental Models and Clinical Trials of Parkinson's Disease.
Schepici G; Silvestro S; Bramanti P; Mazzon E
Int J Mol Sci; 2020 Jul; 21(13):. PubMed ID: 32635541
[TBL] [Abstract][Full Text] [Related]
19. Intranasal insulin protects against substantia nigra dopaminergic neuronal loss and alleviates motor deficits induced by 6-OHDA in rats.
Pang Y; Lin S; Wright C; Shen J; Carter K; Bhatt A; Fan LW
Neuroscience; 2016 Mar; 318():157-65. PubMed ID: 26777890
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotective Effects of Thymol, a Dietary Monoterpene Against Dopaminergic Neurodegeneration in Rotenone-Induced Rat Model of Parkinson's Disease.
Javed H; Azimullah S; Meeran MFN; Ansari SA; Ojha S
Int J Mol Sci; 2019 Mar; 20(7):. PubMed ID: 30934738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
